Publication:
Effectiveness and safety of nutritional supplements in the treatment of hereditary retinal dystrophies: a systematic review.

dc.contributor.authorBrito-García, N
dc.contributor.authorDel Pino-Sedeño, T
dc.contributor.authorTrujillo-Martín, M M
dc.contributor.authorCoco, R M
dc.contributor.authorRodríguez de la Rúa, E
dc.contributor.authorDel Cura-González, I
dc.contributor.authorSerrano-Aguilar, P
dc.date.accessioned2023-01-25T09:42:34Z
dc.date.available2023-01-25T09:42:34Z
dc.date.issued2016-12-09
dc.description.abstractThe hereditary retinal dystrophies (HRDs) are a group of genetically determined disorders that result in loss of the visual function. There is a lack of standard pharmacological treatments or widely accepted nutritional recommendations. The objective of this review is to summarise the scientific evidence on the effectiveness and safety of nutritional supplements for the treatment of HRDs. We conducted a scientific literature search on Medline and PreMedline, EMBASE, SCI-EXPANDED, SSCI, and The Cochrane Library up to August 2014. Experimental, quasi-experimental and controlled observational studies were selected. Eight studies were ultimately included, seven on retinitis pigmentosa (RP) and one on Best disease. Vitamin A, vitamin E, docosahexaenoic acid (DHA), lutein and β-carotene were assessed. A 15 000 IU daily dose of vitamin A was reported to have shown a small protective effect on the progression of RP, as was the use of the carotenoids lutein and β-carotene. Different DHA doses has no effect on RP or Best disease. No supplement showed severe adverse effects in the selected studies although strong evidence of toxicity exists for high doses of vitamin A and β-carotene in certain populations. The selected studies concluded that there may be a small beneficial effect of vitamin A, lutein and β-carotene on the progression of RP. The limited evidence available indicates some well-designed additional studies on combined supplements strategies may achieve more robust conclusions. Moreover, the scarcity of evidence available on the treatment of HRD other than RP with nutritional supplements supports the need for further research efforts.
dc.identifier.doi10.1038/eye.2016.286
dc.identifier.essn1476-5454
dc.identifier.pmcPMC5306468
dc.identifier.pmid27935602
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306468/pdf
dc.identifier.unpaywallURLhttps://www.nature.com/articles/eye2016286.pdf
dc.identifier.urihttp://hdl.handle.net/10668/10668
dc.issue.number2
dc.journal.titleEye (London, England)
dc.journal.titleabbreviationEye (Lond)
dc.language.isoen
dc.organizationHospital Universitario Virgen del Rocío
dc.organizationHospital Universitario Virgen Macarena
dc.page.number273-285
dc.pubmedtypeJournal Article
dc.pubmedtypeReview
dc.pubmedtypeSystematic Review
dc.rights.accessRightsopen access
dc.subject.meshAntioxidants
dc.subject.meshCarotenoids
dc.subject.meshDietary Supplements
dc.subject.meshDisease Progression
dc.subject.meshElectroretinography
dc.subject.meshHumans
dc.subject.meshRetinal Dystrophies
dc.subject.meshVisual Acuity
dc.subject.meshVisual Perception
dc.subject.meshVitamins
dc.titleEffectiveness and safety of nutritional supplements in the treatment of hereditary retinal dystrophies: a systematic review.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number31
dspace.entity.typePublication

Files